Journal
CANCER CELL
Volume 24, Issue 4, Pages 542-556Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2013.09.008
Keywords
-
Categories
Funding
- Komen for the Cure [KG110464]
- the Department of Defense [BC123187]
- the Brewster Foundation
- the National Institutes of Health [RO1CA134519, RO1CA141062]
- Champalimaud Foundation
- European Research Council [269081]
- Deutsche Forschungsgemeinschaft
- Preclinical Imaging and Flow Cytometry Shared Resources of the Cancer Institute of New Jersey [P30CA072720]
Ask authors/readers for more resources
Understanding the mechanism by which tumor cells influence osteoclast differentiation is crucial for improving treatment of osteolytic metastasis. Here, we report broad microRNA (miRNA) expression changes in differentiating osteoclasts after exposure to tumor-conditioned media, in part through activation of NF kappa B signaling by soluble intracellular adhesion molecule (sICAM1) secreted from bone-metastatic cancer cells. Ectopic expression of multiple miRNAs downregulated during osteoclastogenesis suppresses osteoclast differentiation by targeting important osteoclast genes. Intravenous delivery of these miRNAs in vivo inhibits osteoclast activity and reduces osteolytic bone metastasis. Importantly, serum levels of sICAM1 and two osteoclast miRNAs, miR-16 and miR-378, which are elevated in osteoclast differentiation, correlate with bone metastasis burden. These findings establish miRNAs as potential therapeutic targets and clinical biomarkers of bone metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available